Medical School of Ningbo University, Ningbo 315211, China.
Pharmacol Rep. 2011;63(1):157-64. doi: 10.1016/s1734-1140(11)70410-8.
Fibrates are a group of peroxisome proliferator-activated receptor α agonists used in the treatment of dyslipidemia; however, they have been reported to cause species-related hepatocarcinogenesis and clinical myotoxicity. Gemfibrozil is one of the most commonly used fibrates, and it shows the highest risk for myotoxicity among the fibrates. The inhibitory drug-drug interaction mechanism associated with gemfibrozil has been explored recently, and the induction of human P450 3A4 and 2C8 has been reported. In this study, in vivo induction of rat P450 by gemfibrozil was studied in Sprague-Dawley rats. After the rats were dosed with gemfibrozil by oral gavage, microsomes were prepared. The metabolic activities of P450 3A1/2, 2C6, and 2D2 were assayed using probe substrates, and the systemic concentration of gemfibrozil during its administration was determined. P450 3A1/2 and 2C6 activities were induced 32-77% in the rats by gemfibrozil when the exposure concentration was in the clinical range. These data indicate that the inducibility of homologous P450 isoforms by gemfibrozil is similar in Sprague-Dawley rats and in humans. Inductive drug-drug interactions and inhibitory actions are involved in the co-administration of gemfibrozil with other drugs, which suggests the relevance for a fibrate-toxicology investigation.
贝特类药物是一组过氧化物酶体增殖物激活受体α激动剂,用于治疗血脂异常;然而,它们已被报道会引起与物种相关的肝癌发生和临床肌毒性。吉非贝齐是最常用的贝特类药物之一,它在贝特类药物中显示出最高的肌毒性风险。最近已经探索了与吉非贝齐相关的抑制性药物相互作用机制,并报告了对人 P450 3A4 和 2C8 的诱导。在这项研究中,研究了吉非贝齐在 Sprague-Dawley 大鼠体内对 P450 的诱导作用。大鼠经口灌胃给予吉非贝齐后,制备微粒体。使用探针底物测定 P450 3A1/2、2C6 和 2D2 的代谢活性,并测定给药期间吉非贝齐的系统浓度。当暴露浓度在临床范围内时,吉非贝齐使大鼠的 P450 3A1/2 和 2C6 活性诱导 32-77%。这些数据表明,吉非贝齐对同源 P450 同工酶的诱导能力在 Sprague-Dawley 大鼠和人类中相似。吉非贝齐与其他药物联合使用涉及诱导性药物相互作用和抑制作用,这表明需要进行贝特类药物毒理学研究。